Recon: China-US health regulatory dialogue at Biden-Xi summit; Pan-EU launch requirement could bring challenges

• China-US Health Regulatory Dialogue In Crosshairs Amid Biden-Xi Summit (Pink Sheet)
• To get things done fast at FDA: ‘Don’t tell anybody,’ cancer chief says (STAT)
• Can post-market evidence generation be streamlined? FDA-commissioned report proposes solutions (Endpoints)
• Backed by ex-Google CEO Eric Schmidt, a new nonprofit looks to 'solve science' with AI (Endpoints)

• U.K. approves world’s first CRISPR-based medicine, giving green light to therapy for sickle cell, thalassemia (STAT)
• Ozempic shortages have European countries exploring bans on use of popular drug for weight loss (Endpoints)
• WHO Working On ‘Evolved’ Model For COVID-19 Licensing Platform (Pink Sheet)
• New African Platform To Build Up Drug Production & Supply Chains (Pink Sheet)
• Stakeholders To ‘Voice Concerns’ On Future Guidelines For Canada’s Controversial Pricing Mechanism (Pink Sheet)
• RWE Accepted As ‘Primary Evidence’ In 20% Of NICE Appraisals Over Past Year (Pink Sheet)
• Korea’s Powerhouse Ambitions Build On Innovation-Fostering Policies (Pink Sheet)
• Eli Lilly plans new 2 billion euro German plant (Reuters)

• EU Legislative Reform: Pan-EU Launch Requirement Will ‘Take Two To Tango’ (Pink Sheet)
• FDA hands down approval for Bristol Myers' lung cancer drug from Turning Point buyout (Endpoints)
• Pharmas and physicians value medical affairs and MSLs, but have different content priorities, survey says (Endpoints)
• How viral TikTok trends are catching on in pharma marketing (Endpoints)
• FDA cites Dr. Reddy’s for quality control problems at a biologics plant (STAT)
• Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation (STAT)

• 3M names new healthcare spinoff as Solventum (Reuters)
• Abbott study links aspirin-free regimen to better outcomes in heart pump patients (MedTech Dive) 
• Olympus receives Class I recall label for another bronchoscope safety issue (MedTech Dive)

• House panel passes PBM reforms, ratcheting up chance for passage (STAT)
• House moves to limit so-called gain-of-function research (STAT)